Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Guizhou Univ. FAK compound 16c: sourced facts only. name: "Among the synthesized derivatives, compound 16c distinguished itself as a highly potent inhibitor, showing an IC50 value of 5.8 nM against FAK and robust antiproliferative activities in U87-MG (IC50 = 6.6 nM) and U118-MG (IC50 = 4.3 nM) GBM cell lines." [PMID:42019175]; target: "Among the synthesized derivatives, compound 16c distinguished itself as a highly potent inhibitor, showing an IC50 value of 5.8 nM against FAK and robust antiproliferative activities in U87-MG (IC50 = 6.6 nM) and U118-MG (IC50 = 4.3 nM) GBM cell lines." [PMID:42019175]; developer: "School of Pharmaceutical Sciences, Guizhou University, Guiyang, 550025, China." [PMID:42019175]; stage: "Importantly, the oral bioavailability of 16c reached 18.7% at a dose of 10 mg/kg, and 16c displayed pronounced antitumor efficacy in the absence of detectable systemic toxicity in a U87-MG xenograft model." [PMID:42019175]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Guizhou Univ. FAK compound 16c.